Alnylam Pharma (ALNY) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $165.00 -5.17%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.58), $0.05 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $11 million versus the consensus estimate of $8.93 million.
At September 30, 2014, Alnylam had cash, cash equivalents and total marketable securities of $915.2 million, as compared to $350.5 million at December 31, 2013.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Oxford Square Capital Corp. (OXSQ) Misses Q3 EPS by 1c
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
